OBJECTIVE: To explore the pharmacology actions of Cyclovirobuxinum D (Cvb-D) for the myocardial ischemia and study its possible mechanism. METHODS: The rats were given orally with Cvb-D 0.55 g/kg, 1.1 g/kg and 2.2 g/kg per day, for 21 days. The myocardial ischemia model were induced by isoprenaline. The rats ECG, serum CPK, LDH, FFA and myocardium tissue SOD, MDA level were detected. RESULTS: Cvb-D could significantly reduce myocardial ischemia model induced by isoprenaline rats' sigmaJ of ECG, shorten ECG resume time, reduce serum FFA content, serum CPK, LDH activation, reduce cardiac tissue MDA content, raise the cardiac tissue SOD activation. CONCLUSION: Cvb-D can decrease the release of FFA, CPK, LDH and improve the model rats' myocardium MDA, SOD level. It may be some of mechanisms of its anti-myocardial ischemia effect.
OBJECTIVE: To explore the pharmacology actions of Cyclovirobuxinum D (Cvb-D) for the myocardial ischemia and study its possible mechanism. METHODS: The rats were given orally with Cvb-D 0.55 g/kg, 1.1 g/kg and 2.2 g/kg per day, for 21 days. The myocardial ischemia model were induced by isoprenaline. The rats ECG, serum CPK, LDH, FFA and myocardium tissue SOD, MDA level were detected. RESULTS:Cvb-D could significantly reduce myocardial ischemia model induced by isoprenalinerats' sigmaJ of ECG, shorten ECG resume time, reduce serum FFA content, serum CPK, LDH activation, reduce cardiac tissue MDA content, raise the cardiac tissue SOD activation. CONCLUSION:Cvb-D can decrease the release of FFA, CPK, LDH and improve the model rats' myocardium MDA, SOD level. It may be some of mechanisms of its anti-myocardial ischemia effect.
Authors: Qing Liu; Jiqiang Li; Jing Wang; Jianping Li; Joseph S Janicki; Daping Fan Journal: Evid Based Complement Alternat Med Date: 2013-10-31 Impact factor: 2.629